SOCIETY OF NEUROSCIENCE ANNUAL MEETING TO BE HELD 

by | Sep 23, 2023 | News & Media

November 11-15, 2023

Biolexis Therapeutics Scientific Team participates and present their pre-clinical stage small molecule HDAC6 inhibitor program for ALS indication at the “SfN” (Society of Neuroscience) Annual Meeting to be held on Nov 11-15, 2023 – Walter E. Washington Convention Center in Washington, D.C.

https://www.sfn.org/meetings/neuroscience-2023

Abstract Title: Development of a Novel, Orally Active, Brain Penetrable HDAC6 Inhibitors Shows a Therapeutic Potential for Amyotrophic Lateral Sclerosis (ALS)

Session Title: ALS: Non-Human Models

Session Type: Poster | Abstract Control Number: 2773
Session Number: PSTR200 | Presentation Number: PSTR200.26
Session Date and Time: 11/13/2023 8:00:00 AM – 11/13/2023 12:00:00 PM
Location/Room: WCC Halls A-C | Presentation Time: Mon. Nov. 13, 2023, 9:00 AM – 10:00 AM

22nd Annual Bio-IT World Conference & Expo

May 16-18, 2023 Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at 22nd Annual Bio-IT World Conference & Expo taking place May 16-18, 2023, in Boston, MA. https://www.bio-itworldexpo.com/

Ai-Driven Drug Development Summit

April 26-27, 2023 Biolexis CEO Dr. David J. Bearss to present MolecuLern technology at Ai-Driven Drug Development Summit Europe on April 26-27, 2023, in London. AI Driven Drug Development Summit Europe 2023 (aidrugdevelopmentsummiteu.com)